861857-73-0

Upstream product

• 861857-74-1 2-methyl-propane-2-sulfinic acid [8-(3-bromo-phenyl)-1,4-dioxa-spiro[4.5]dec-8-yl]-amide 
• 861857-71-8 2-methyl-propane-2-sulfinic acid (1,4-dioxa-spiro[4.5]dec-8-ylidene)-amide 
• 861857-89-8 8-(3-bromo-phenyl)-1,4-dioxa-spiro[4.5]dec-8-ylamine hydrochloride 
• 591-18-4 1-Bromo-3-iodobenzene 

Downstream Products

• 861857-89-8 8-(3-bromo-phenyl)-1,4-dioxa-spiro[4.5]dec-8-ylamine hydrochloride 
• 861857-90-1 [3-[8-(3-bromo-phenyl)-1,4-dioxa-spiro[4.5]dec-8-ylamino]-(1S,2R)-1-(3,5-difluoro-benzyl)-2-hydroxy-propyl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

OXIME DERIVATIVE HYDROXYETHYLAMINE ASPARTYL-PROTEASE INHIBITORS

The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS

The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a colletion of diseases, disorders, and conditions associated with abnormal deposition of A-beta protei

METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INHIBITORS

The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.